Candidate multi‐epitope vaccines in aluminium adjuvant induce high levels of antibodies with predefined multi‐epitope specificity against HIV‐1

Some neutralizing epitopes on HIV‐1 envelope proteins were identified to induce antibodies which could effectively inhibit the infection of different strains in vitro. But only very low levels of these antibodies were determined in the HIV‐1 infected individuals. To increase the levels of protective antibodies in vivo, we suggested multi‐epitope vaccine as a new strategy to induce high level of neutralization antibodies with predefined multi‐epitope specificity. A synthesized epitope peptide MP (CG‐GPGRAFY‐G‐ELDKWA‐G‐RILAVERYLKD) containing three neutralizing epitopes (GPGRAFY, ELDKWA, RILAVERYLKD) was conjugated to carrier protein KLH, and then used for immunization in mouse together with aluminium adjuvant or Freund's adjuvant (FA). The candidate MP‐KLH multi‐epitope vaccine in aluminium adjuvant could induce antibody response very strongly to the epitope peptide C‐(RILAVERYLKD‐G) 2 and the immunosuppressive peptide (P1) (LQARILAVERYLKDQQL) (antibody titer: 1:51 200), strongly to the epitope peptide C‐(ELDKWA‐G) 4 and the C‐domain peptide (P2) (1:12 800), and moderately to the epitope peptide C‐(GPGRAFY) 4 and the V3 loop peptide (1:1600). The immunoblotting analysis demonstrated that the antibodies in sera could recognize P1, P2, V3 loop peptides and rsgp41 (aa 539–684). These results are similar with that in the case of PI‐BSA in FA, and suggest that the multi‐epitope vaccine in aluminium could induce high levels of antibodies of predefined multi‐epitope specificity, which provides experimental evidence for the new strategy to develop an effective neutralizing antibody‐based multi‐epitope vaccine against HIV‐1.